N/A N=60 The Medtronic CoreValve™ Evolut R™ CE Mark Clinical Study
Aortic Stenosis
Primary: All-cause Mortality Rate at 30 Days — 0.0 percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=38 Aging and Estrogen on Cortical Function
Memory Loss · Cognitive Changes · Postmenopausal Symptoms
Primary: Functional Magnetic Resonance Imaging (fMRI) Changes in Response to Estrogen and Aging - Dorsolateral Pre-frontal Cortex (DLPFC) — 455.8; -214.4; -348.1; 90.1 linear…
N/A N=71 Oral Zinc for the Treatment of Acute Diarrhea in US Children
Diarrhea · Gastroenteritis
Primary: Duration of Diarrhea in Acute Diarrheal Illnesses in a Developed Nation While Taking Zinc or Placebo. — 73; 72; 48; 76.8 Hours — p=0.88
Phase 4 N=173 Neurocognitive and Metabolic Effects of Mild Hypothyroidism
Hypothyroidism
Primary: Executive Function — 7.9; 7.5; 8.8 units on a scale
Phase 3 N=405 Safety/Efficacy Study of Oxycodone HCl/Niacin to Treat Pain After Bunionectomy
Pain
Primary: SPID48 — 604.48; 998.46; 1224.97 score on a scale
Phase 2 N=250 Prolongation of the Interval Between Monitoring of Warfarin in Stable Patients
Atrial Fibrillation · Heart Valve Diseases · Venous Thrombosis
Primary: Primary Outcome Measure: Time in Therapeutic Range — 74.1; 71.6 percentage of time
Phase 2 N=118 Safety and Efficacy Study of Enzalutamide in Patients With Advanced, Androgen Receptor-Positive, Triple Negative Breast Cancer
Advanced, Androgen Receptor Positive Triple Negative Breast Cancer
Primary: Percentage of Participants With Clinical Benefit at Week 16: Evaluable Population — 33.3 Percentage of participants
Phase 3 N=335 Safety and Efficacy of T-2345 Compared to Xalatan in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension
Primary Open Angle Glaucoma · Ocular Hypertension
Primary: Intraocular Pressure — -3.0; -3.8; -2.7; -3.6 mm Hg — p=0.0091
N/A N=114 Follow up of Thai Adult Volunteers With Breakthrough HIV Infection After Participation in a Preventive HIV Vaccine Trial
HIV-1
Primary: Number of Participants Reaching Clinical Long Term Component Endpoints — 3; 5; 18; 23 Participants
Phase 4 N=15 Effect of Weight on the Population Pharmacokinetic Analysis of Doxorubicin and Cyclophosphamide
Breast Cancer · Obesity
Primary: Clearance (Cl) for Doxorubicin and Cyclophosphamide — 1.85 L/hr
Phase 3 N=750 Safety and Immunogenicity of GlaxoSmithKline Biologicals Meningococcal Group B Vaccine When Administered Concomitantly With GlaxoSmithKline Biologicals MenACWY Conjugate Vaccine to Healthy Infants
Infections, Meningococcal
Primary: Human Serum Bactericidal Activity (hSBA) Geometric Mean Titers (GMTs) Against Each of the Serogroup B Indicator Strains — 92; 104; 1850; 1790 Titers
Phase 2 N=47 Safety and Efficacy of NVXT Solution in Mild-to-Moderate Fungal Infection of the Toe Nail
Onychomycosis
Primary: Number of Participants With Negative Fungal Culture — 14; 2 Participants
Phase 2 N=145 A Study of Plazomicin Compared With Levofloxacin for the Treatment of Complicated Urinary Tract Infection (cUTI) and Acute Pyelonephritis (AP)
Complicated Urinary Tract Infection · Acute Pyelonephritis
Primary: Percentage of Patients Who Attained Microbiological Eradication (MBE) at the Test of Cure (TOC) Visit in the Microbiological Intent to Treat (MITT) Population — 50…
Phase 2 N=9 Pomalidomide or Lenalidomide and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma Previously Treated With Lenalidomide
Recurrent Plasma Cell Myeloma · Refractory Plasma Cell Myeloma
Primary: Proportion of Confirmed Tumor Responses Defined to be a Partial Response or Better Noted as the Objective Status on Two Consecutive Evaluations — .4; .25 proportion of…
Phase 2 N=106 Pediatric Philadelphia Positive Acute Lymphoblastic Leukemia
Leukemia, Pediatric
Primary: 3-year Event-free Survival (EFS) Rate — 66.0 Percentage of Participants — p=0.032